Cancer Science Institute of Singapore’s Post

Early on, the St. Baldrick’s founders were interested in making sure there was a pipeline of qualified investigators studying childhood #cancer, so Dr. Jeff Lipton first suggested funding fellowships in order to build that pipeline. He felt young physician scientists who showed potential as cancer #researchers may not have been convinced that pediatric #oncology was a viable career path. To help ensure those fellowships were funded as effectively as possible, Dr. Lipton also involved #scientists from throughout the pediatric cancer community to be part of the discussion – including what is now the Foundation’s Scientific Advisors, and more than 200 other pediatric oncology #research experts who serve as scientific reviewers. The result is a grant-making process that Dr. Lipton calls “the envy of the scientific community.” This focus on training the next generation of pediatric oncology researchers led to more grants funding more research – moving far beyond the original training grants – and more doctors taking notice. The evolution continued over nearly 25 years of head-shaving, with Dr. Lipton saying the pipeline of young doctors entering the field is now “more robust than I thought it would be.” #researchishope #researchmatters #acceleratethenext25

#liquidbiopsy #pancreaticcancer #cancerresearch #oncology https://lnkd.in/e3-W2xus Pancreatic-cancer test with 97% accuracy A #blood #test has detected early-stage pancreatic cancer with 97% accuracy in an unpublished clinical trial involving 984 people. The ‘liquid biopsy’ analysed #microRNAs trapped inside small vesicles called #exosomes in the blood, as well as the levels of the protein CA19-9, which is known to be associated with pancreatic cancer.

Two Mayo Clinic graduate students from the same hometown share their journey to becoming Ph.D. researchers who study regenerative medicine and new approaches to treating cancer. Mexican pride: the journey of two young Mexican researchers to the elite, by Jose Arrieta. They say that dreams that are pursued with perseverance always come true, and two young researchers, originally from Juárez, can confirm this, because thanks to their efforts they stand out in a world-renowned institution. Claudia Martínez and Omar Gutiérrez saw their dreams come true when they were integrated into the research team at the Mayo Clinic, known for its research in various medical specialties. “For my doctorate, I wanted my education to be oriented toward immunotherapy and cancers, but to try to apply it as a more translational concept, so that what we develop in the laboratory has the potential to be used in a clinical trial. Mayo Clinic is one of the few institutions in the United States that has the funds, machinery and research departments to be able to finance clinical trials,” explains Martínez. Article: Orgullo mexicano: la travesía de dos jóvenes investigadores mexicanos a la élite | El Heraldo de México (https://bit.ly/4be8eNo)

Oportunidades de postdoctorado en genómica, bioinformática y oncología. The AACR Maximizing Opportunity for New Advancements in Research in Cancer (MONARCA) Grant for Latin America represents an AACR initiative to address this need by promoting and supporting early-career investigators in Latin America to establish a successful career path in cancer research, thereby increasing and sustaining a cadre of talented cancer researchers in Latin America. https://lnkd.in/emZbXcdw

DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for the stratification of metastatic breast cancer patients to HER2-targeting therapies. The recently published trial result indicates the relevance of assessing biomarker expression in Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based CELLSEARCH® platform. https://lnkd.in/ddUEeAiT #CTC #Liquidbiopsy #biomarker #HER2 #breastcancer #CTCcharacterization CELLSEARCH Circulating Tumor Cell Kit is not cleared or approved for use to guide specific treatment decisions. For more information on the full intended use and limitations of the CELLSEARCH system, please refer to the Instructions for Use at https://lnkd.in/da4FK-hz

DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for the stratification of metastatic breast cancer patients to HER2-targeting therapies. The recently published trial result indicates the relevance of assessing biomarker expression in Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based CELLSEARCH® platform. https://lnkd.in/ddUEeAiT #CTC #Liquidbiopsy #biomarker #HER2 #breastcancer #CTCcharacterization CELLSEARCH Circulating Tumor Cell Kit is not cleared or approved for use to guide specific treatment decisions. For more information on the full intended use and limitations of the CELLSEARCH system, please refer to the Instructions for Use at https://lnkd.in/da4FK-hz

Congratulations to medical student Kimya Ghaffarian on receiving a 2024 Breakthrough Cancer Research Summer Student Scholarship to fund research into use of a smartphone application platform for Radiotherapy patients. This award partners students with research teams in CancerResearch to foster the education of the next generation of cancer research leaders. We asked Kimya to tell us about her study. "Radiotherapy is a highly effective treatment option for patients dealing with cancer but it is often underutilised due to a lack of awareness and perceived negative impact on a patient’s quality of life. This study aims to use a smartphone application platform called ONCOpatient® to fill this knowledge gap and collect data on how radiotherapy impacts a patient’s health-related quality of life. This platform will allow us to facilitate the collection of data remotely, saving patients who are often very sick and their caregivers from making repeated trips to the hospital to complete questionnaires. Using this data, we aim to help healthcare practitioners identify patients who may benefit most from treatment, assess resources that may (or may not) be available to patients and to provide information to aid in the treatment decision-making process."

Alpenglow Biosciences to receive up to $21M through ARPA-H and NIH as part of the Cancer Moonshot initiative Portfolio company Alpenglow Biosciences, a company reshaping pathology with their 3D spatial biology platform, announced they were awarded up to up to $21M in contracts from Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH). The contract also included partners Liu Biophotonics Lab at University of Washington, the Mahmood AI Lab at Harvard & Mass General Brigham, and Vanderbilt University Medical Center to develop a breakthrough technology for surgical oncology. The five-year ARPA-H contract is part of the Cancer Moonshot initiative spearheaded by the Biden administration. Alpenglow, alongside elite academic medical centers, is set to transform the fight against cancer with its innovative AI-driven 3D Spatial Biology platform. Press Release: https://lnkd.in/dxTJUzcq #spatialbiology #oncology #drugdiscovery

If you want to know where NIH puts its money, check out this graphic of the major institutes and the FY2025 budget request. Although NCI dominates the NIH funding landscape, it is important to recognize that the lines between these funding agencies and the subject matter they fund is becoming increasingly blurred. For example, the relationship between cancer, neuroscience, and aging  (NCI, NINDS, NIA) is showing overlap. It is a daunting task to read every funding opportunity from every institute. Let Astound simplify this for you by matching your scientific keywords to relevant opportunities from NIH, DoD, NSF, and foundations. It happens in seconds. We not only help you drill down on the right opportunity but we also help create a short-term and long-term funding plan customized to your funding needs. Check us out at https://lnkd.in/egbeterU or email us directly at info@astoundresearch.com Also, check out my webinar on the Flow of Money in Science at BiteSize Bio.

🚀 Exciting news from Cordance Medical! They've just secured a $399,358 award from U.S. Department of Health and Human Services (HHS), specifically The National Institutes of Health and the NIH National Cancer Institute. This funding is set to revolutionize brain tumor diagnostics with their innovative NeuroAccess System. By optimizing non-invasive focused ultrasound for brain tumor liquid biopsy, Cordance Medical aims to address the critical need for effective blood-based molecular characterization in brain cancer patients. 🔬 The project focuses on ensuring the safety and efficacy of the NeuroAccess System, which uses focused ultrasound and microbubbles to open the blood-brain barrier non-invasively. This allows biomarkers to enter systemic circulation, facilitating liquid biopsies where traditional methods fall short. This groundbreaking research is part of a project grant and will span approximately 11 months, starting from September 2024 and concluding in August 2025. #Innovation #Healthcare #SBIR #STTR #CancerResearch #MedicalBreakthrough